BioWorld Asia

April 14, 2004

Adprotech Being Acquired By Inflazyme In C$20M Deal

LONDON - Last week, shareholders in privately held Adprotech Ltd. agreed to be taken over by Inflazyme Pharmaceuticals Ltd. for about C$20 million (US$14.9 million) in shares. (BioWorld International) Read More

EuropaBio Probes Fairness To Biotech In New EU Rules

Interfering RNA Libraries Might Boost Mammalian Gene Insight

Start-up Opsona Focused On Toll-Like Receptor Signaling

Although Cleared For Planting, Bayer Ditching UK Maize Plans

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...